Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the ...

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, toda ...

Market technician Jonathan Krinsky analyzes the shift in market leadership from technology to healthcare amid recent ...

BTIG research firm reiterated its Buy rating and $21.00 price target for INmune Bio Inc. (NASDAQ:INMB), currently trading at ...

(Nasdaq: LFMD), a leading provider of virtual primary care services, today announced its participation in the 12 th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference ...

Papa Johns’ blueprint under CEO Todd Penegor has several targets, from a return to core strength focus to data leverage to ...

BTIG analysts began covering Arcturus Therapeutics (NASDAQ:ARCT) with a positive outlook, assigning a Buy rating and establishing a price target of $41.00. Currently trading at $16.49 with a market ...

BTIG initiated coverage of Arcturus Therapeutics (ARCT) with a Buy rating and $41 price target Arcturus is a commercial-stage biotechnology ...

What damage might Monday's ongoing selloff do to the technical set-up for stocks? Well, in a note published on Sunday, BTIG chartist guru Jonathan Krinsky observed that Friday's action had already sug ...

Physicians also expect greater use of Johnson & Johnson’s Varipulse system over the next two years despite the company’s ...

CAD to Participate in the BTIG at Snowbird:12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference NASHUA, N.H., Jan. 27, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ...

BTIG raised the firm’s price target on Intuitive Surgical (ISRG) to $622 from $561 and keeps a Buy rating on the shares after ...